A citation-based method for searching scientific literature

Suyan Duan, Fang Lu, Dandan Song, Chengning Zhang, Bo Zhang, Changying Xing, Yanggang Yuan. Front Endocrinol (Lausanne) 2021
Times Cited: 3







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Diabetic nephropathy and cardiovascular diseases.
S Czekalski. Rocz Akad Med Bialymst 2005
5
33

Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial.
João Pedro Ferreira, Paula Abreu, John J V McMurray, Dirk J van Veldhuisen, Karl Swedberg, Stuart J Pocock, John Vincent, Katharina Lins, Patrick Rossignol, Bertram Pitt,[...]. Eur J Heart Fail 2019
29
33

Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
Jonatan Barrera-Chimal, Sophie Girerd, Frederic Jaisser. Kidney Int 2019
81
33

True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis.
Davor Vukadinović, Daniel Lavall, Aleksandra Nikolovska Vukadinović, Bertram Pitt, Stefan Wagenpfeil, Michael Böhm. Am Heart J 2017
38
33

Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy.
Li-Jing Sun, Yan-Ni Sun, Jian-Ping Shan, Geng-Ru Jiang. J Diabetes Investig 2017
27
33

Safety and Antihypertensive Effect of Selara® (Eplerenone): Results from a Postmarketing Surveillance in Japan.
Shoko Takahashi, Megumi Hiramatsu, Shinichi Hotta, Yukie Watanabe, Osamu Suga, Yutaka Endo, Isamu Miyamori. Int J Hypertens 2016
5
33

Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress.
Hui Chen, Feng Sun, Xiaoshi Zhong, Yuebin Shao, Ashio Yoshimura, Yan Liu. Kidney Blood Press Res 2013
30
33

The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial.
Hitoshi Minakuchi, Shu Wakino, Hidenori Urai, Arata Kurokochi, Kazuhiro Hasegawa, Takeshi Kanda, Hirobumi Tokuyama, Hiroshi Itoh. Sci Rep 2020
11
33

Diabetic Nephropathy: An Overview.
Manpreet K Sagoo, Luigi Gnudi. Methods Mol Biol 2020
40
33

Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus.
Shigehiro Karashima, Takashi Yoneda, Mitsuhiro Kometani, Masashi Ohe, Shunsuke Mori, Toshitaka Sawamura, Kenji Furukawa, Masakazu Yamagishi, Yoshiyu Takeda. Clin Exp Hypertens 2016
8
33

Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?
Antonis A Manolis, Theodora A Manolis, Helen Melita, Antonis S Manolis. Curr Hypertens Rep 2019
10
33

A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease.
Naoki Sato, Masayoshi Ajioka, Takahisa Yamada, Masaharu Kato, Masafumi Myoishi, Takashi Yamada, So-Young Kim, Christina Nowack, Peter Kolkhof, Tsuyoshi Shiga. Circ J 2016
31
33


Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus.
Hylton V Joffe, Raymond Y Kwong, Marie D Gerhard-Herman, Caitlin Rice, Kathryn Feldman, Gail K Adler. J Clin Endocrinol Metab 2007
58
33

Particulate Matter and Albuminuria, Glomerular Filtration Rate, and Incident CKD.
Matthew F Blum, Aditya Surapaneni, James D Stewart, Duanping Liao, Jeff D Yanosky, Eric A Whitsel, Melinda C Power, Morgan E Grams. Clin J Am Soc Nephrol 2020
29
33

Mineralocorticoid Receptor and Cardiovascular Disease.
Mathieu Buonafine, Benjamin Bonnard, Frédéric Jaisser. Am J Hypertens 2018
38
33

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.
Nina Vodošek Hojs, Sebastjan Bevc, Robert Ekart, Nejc Piko, Tadej Petreski, Radovan Hojs. Pharmaceuticals (Basel) 2021
6
33


Aldosterone mediates glomerular inflammation in experimental mesangial proliferative glomerulonephritis.
Danping Qin, Hiroyuki Morita, Kiyoko Inui, Hironori Tayama, Yoshihiko Inoue, Ashio Yoshimura. J Nephrol 2013
15
33


Diabetic Kidney Disease: Challenges, Progress, and Possibilities.
Radica Z Alicic, Michele T Rooney, Katherine R Tuttle. Clin J Am Soc Nephrol 2017
729
33

Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial.
Niels H Brandt-Jacobsen, Marie Louise Johansen, Jon Rasmussen, Julie L Forman, Maria Refsgaard Holm, Jens Faber, Patrick Rossignol, Morten Schou, Caroline Kistorp. Diabetes Metab 2021
5
33


Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
Larbi Amazit, Florian Le Billan, Peter Kolkhof, Khadija Lamribet, Say Viengchareun, Michel R Fay, Junaid A Khan, Alexander Hillisch, Marc Lombès, Marie-Edith Rafestin-Oblin,[...]. J Biol Chem 2015
58
33


Managing diabetic kidney disease.
Sagen Zac-Varghese, Peter Winocour. Br Med Bull 2018
7
33

Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study.
Kamlesh Khunti, Bernard Charbonnel, Hungta Chen, David Z Cherney, Andrew Cooper, Peter Fenici, Marilia B Gomes, Niklas Hammar, Hiddo J L Heerspink, Linong Ji,[...]. Diabetes Obes Metab 2021
3
33

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Murray Epstein, Gordon H Williams, Myron Weinberger, Andrew Lewin, Scott Krause, Robin Mukherjee, Rajiv Patni, Bruce Beckerman. Clin J Am Soc Nephrol 2006
300
33

Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends.
Moien Abdul Basith Khan, Muhammad Jawad Hashim, Jeffrey Kwan King, Romona Devi Govender, Halla Mustafa, Juma Al Kaabi. J Epidemiol Glob Health 2020
325
33


[Antifibrotic renal role of mineralcorticoid receptor antagonists].
Alessandra Ocello, Sandra La Rosa, Fulvio Fiorini, Salvatore Randone, Rosario Maccarrone, Giorgio Battaglia, Antonio Granata. G Ital Nefrol 2019
1
100


Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Hiddo J L Heerspink, Bergur V Stefansson, Glenn M Chertow, Ricardo Correa-Rotter, Tom Greene, Fan-Fan Hou, Magnus Lindberg, John McMurray, Peter Rossing, Roberto Toto,[...]. Nephrol Dial Transplant 2020
97
33

Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients.
Atsuko Kamijo-Ikemori, Takeshi Sugaya, Takashi Yasuda, Takehiro Kawata, Akio Ota, Shinobu Tatsunami, Ruriko Kaise, Toshihiko Ishimitsu, Yasushi Tanaka, Kenjiro Kimura. Diabetes Care 2011
96
33

Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression.
Chi-Yuan Hsu, Dawei Xie, Sushrut S Waikar, Joseph V Bonventre, Xiaoming Zhang, Venkata Sabbisetti, Theodore E Mifflin, Josef Coresh, Clarissa J Diamantidis, Jiang He,[...]. Kidney Int 2017
57
33

Guidelines for clinical evaluation of chronic kidney disease : AMED research on regulatory science of pharmaceuticals and medical devices.
Eiichiro Kanda, Naoki Kashihara, Kunihiro Matsushita, Tomoko Usui, Hirokazu Okada, Kunitoshi Iseki, Kenichi Mikami, Tetsuhiro Tanaka, Takashi Wada, Hirotaka Watada,[...]. Clin Exp Nephrol 2018
13
33

Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules.
Atsuko Kamijo, Takeshi Sugaya, Akihisa Hikawa, Mitsuhiro Okada, Fumikazu Okumura, Masaya Yamanouchi, Akiko Honda, Masaru Okabe, Tomoya Fujino, Yasunobu Hirata,[...]. Am J Pathol 2004
174
33


A basic science view of acute kidney injury biomarkers.
Jennifer R Charlton, Didier Portilla, Mark D Okusa. Nephrol Dial Transplant 2014
159
33

Assessment of urinary NGAL for differential diagnosis and progression of diabetic kidney disease.
Suyan Duan, Jiajia Chen, Lin Wu, Guangyan Nie, Lianqin Sun, Chengning Zhang, Zhimin Huang, Changying Xing, Bo Zhang, Yanggang Yuan. J Diabetes Complications 2020
11
33

Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
Claire C J Dekkers, Sergei Petrykiv, Gozewijn D Laverman, David Z Cherney, Ron T Gansevoort, Hiddo J L Heerspink. Diabetes Obes Metab 2018
113
33

Current updates on protein as biomarkers for diabetic kidney disease: a systematic review.
Rani Sauriasari, Dhonna Dwi Safitri, Nuriza Ulul Azmi. Ther Adv Endocrinol Metab 2021
2
50

Impact of sleep duration on obesity and the glycemic level in patients with type 2 diabetes: the Fukuoka Diabetes Registry.
Toshiaki Ohkuma, Hiroki Fujii, Masanori Iwase, Yohei Kikuchi, Shinako Ogata, Yasuhiro Idewaki, Hitoshi Ide, Yasufumi Doi, Yoichiro Hirakawa, Udai Nakamura,[...]. Diabetes Care 2013
84
33

Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014.
Maryam Afkarian, Leila R Zelnick, Yoshio N Hall, Patrick J Heagerty, Katherine Tuttle, Noel S Weiss, Ian H de Boer. JAMA 2016
404
33

Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014.
Shinji Kume, Shin-Ichi Araki, Satoshi Ugi, Katsutaro Morino, Daisuke Koya, Yoshihiko Nishio, Masakazu Haneda, Atsunori Kashiwagi, Hiroshi Maegawa. J Diabetes Investig 2019
24
33

Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus.
Gudeta D Fufaa, E Jennifer Weil, Robert G Nelson, Robert L Hanson, Joseph V Bonventre, Venkata Sabbisetti, Sushrut S Waikar, Theodore E Mifflin, Xiaoming Zhang, Dawei Xie,[...]. Diabetologia 2015
65
33

Urinary podocyte-associated mRNA levels correlate with proximal tubule dysfunction in early diabetic nephropathy of type 2 diabetes mellitus.
Ligia Petrica, Sorin Ursoniu, Florica Gadalean, Adrian Vlad, Gheorghe Gluhovschi, Victor Dumitrascu, Daliborca Vlad, Cristina Gluhovschi, Silvia Velciov, Flaviu Bob,[...]. Diabetol Metab Syndr 2017
16
33

Urine NGAL as an early biomarker for diabetic kidney disease: accumulated evidence from observational studies.
Xing-Yao Tang, Jian-Bo Zhou, Fu-Qiang Luo, Yi-Peng Han, Wei Zhao, Zong-Li Diao, Mei Li, Lu Qi, Jin-Kui Yang. Ren Fail 2019
10
33

Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000-2015.
Hui-Teng Cheng, Xiaoqi Xu, Paik Seong Lim, Kuan-Yu Hung. Diabetes Care 2021
28
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.